Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development

Area of Science:

• Immunology and Cancer Therapeutics
• Molecular Biology and Drug Development

Background:

• Metastatic cancer survival has improved with immune checkpoint blockers, but response rates remain limited.
• Existing combination therapies (e.g., PD-1/CTLA-4, PD-1/chemotherapy) face challenges with adverse events.
• T-cell immunoglobulin and ITIM domain (TIGIT) is an inhibitory checkpoint receptor on T cells and NK cells, representing a novel therapeutic target.

Purpose of the Study:

• To review the clinical development of anti-TIGIT antibodies.
• To describe factors influencing early clinical development of these novel agents.
• To summarize available efficacy and safety data and discuss development challenges.

Main Methods:

• Review of pre-clinical and early clinical studies on anti-TIGIT antibodies.
• Analysis of critical factors in antibody design and development (origin, Ig isotype, FCγR binding, dose, schedule).
• Summary of clinical trial data regarding efficacy and safety.

Main Results:

• Five anti-TIGIT antibody molecules are currently in advanced clinical evaluation (Phase II and above).
• Early studies indicate potential for anti-TIGIT antibodies in cancer treatment.
• Key development considerations include antibody characteristics and dosing strategies.

Conclusions:

• Anti-TIGIT antibodies represent a promising new frontier in cancer immunotherapy.
• Careful consideration of antibody properties and clinical trial design is crucial for success.
• Challenges remain in patient selection and securing payer coverage for anti-TIGIT therapies.